BackCytoMed Therapeutics Overview

CytoMed Therapeutics Profit Margin

Latest profit margin for CytoMed Therapeutics: -1065.07% — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

Quarterly Profit Margin

-1030.69%
↑ 49.85% YoY

As of Dec 2025

Annual Profit Margin (TTM)

-1065.07%

Trailing 12 months ending Dec 2025

Average Profit Margin (Comparison Companies)

Loading

Profit Margin History

Loading

Profit Margin Comparison

Loading

Annual Profit Margin Growth Rate (%)

Loading
Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin

CytoMed Therapeutics (GDTC) FAQ

As of the most recent data (December 2025), GDTC shows a profit margin of -1065.07%. That is below the sector sector average of 21.36%. Scroll down for historical charts and peer comparison views.

The its sector sector average profit margin is about 21.36%. CytoMed Therapeutics is at -1065.07%, which is lower that average. That is roughly 5087.0% below the sector mean. Use the comparison chart on this page to see how GDTC stacks up against individual peers as well.

Check the historical chart to see whether GDTC's profit margin is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare CytoMed Therapeutics with peers to see if the move is company-specific or sector-wide.

Besides this profit margin page, Stockcircle has CytoMed Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently -1065.07%) with ownership activity and broader fundamentals.